20 May 2003
Impact of antiviral therapy on the liver steatosis in patients with chronic hepatitis c (chc).
W. Kryczka, D. Zarębska-Michaluk, A. Urbaniak, K. PaluchMed Sci Monit 2003; 9(2): 10-0 :: ID: 15243
Abstract
Background:Liver steatosis is commonly associated with CHC.The aim of our study was to assess the changes in liver steatosis (LS)after antiviral treatment in relation to type of response. Material/Methods: Results of paired liver biopsy (before and at least 12 months after the end of interferon alone or with ribavirin treatment)of 91 CHC patients were compared.Liver specimens were assessed according to Ishak`s criteria;median interval between baseline and 2 nd biopsies was 32 months.69 of them patients (F19/M50;age:43 ±10yrs)were no sustained responders (NSR)and 22 (F12/M10;age:38 ±10yrs)were sustained responders (SR).The control group (CG)was 50 (F25/M25; age:39(13yrs) non-treated CHC patients (interval between 1 st and 2 nd biopsy at least 18 months;median 24 months).The total number of patients with LS (>1%involved hepatocytes)in both biopsies and changes in fibrosis stage were evaluated. Results:Between 1 st and 2 nd biopsy there were no significant changes in mean stage (2.4 ±1.8 vs.2.4 ±1.7 and 0.6 ±0.9 vs. 0.7 ±1.1)as well as in frequency of LS (65%vs.68%and 44% vs.44%)in NSR and CG groups,respectively.In 2 nd biopsy, among SR patients a significant decrease in fibrosis stage was noted (1.7 ±1.4 vs.0.6 ±1.4 in 1 st and 2 nd biopsy respectively; p=0.015)as well as disappearance of LS (in all but one patient).The maximum loss of LS was observed in non-diabetic normolipaemic 44-old women:more than 40%at 1 st and 0%in 2{ig nd}biopsies in the presence of no significant changes in the levels of cholesterol,triglycerides and BMI value. Conclusions: Too small number of patients have made impossible to analyse LS in relation to HCV genotypes but our observations suggest that the loss of steatosis appears before the regression of fibrosis in almost all sustained responders patients.Moreover,our study seems to confirm the reports of the viral nature of liver steatosis in chronic hepatitis C.
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...Med Sci Monit In Press; DOI: 10.12659/MSM.943797
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952